Kallikreins are a subgroup of serine proteases and these proteolytic enzymes have diverse physiological functions in many tissues. Growing evidence suggests that many kallikreins are implicated in carcinogenesis. In rodents, kallikreins constitute a large multigene family, but in humans, only three genes were identified. By using the positional candidate gene approach, we were able to identify a new kallikrein-like gene, tentatively named KLK-L4 (for kallikrein-like gene 4). This new gene maps to chromosome 19q13.3-q13.4, is formed of five coding exons and four introns, and shows structural similarity to other kallikreins and kallikrein-like genes. KLK-L4 is expressed in a variety of tissues including prostate, salivary gland, breast, and testis. Our preliminary results show that KLK-L4 is down-regulated, at the mRNA level, in breast cancer tissues and breast cancer cell lines. Its expression is regulated by steroid hormones in the breast cancer cell line BT-474. This gene may be involved in the pathogenesis and/or progression of breast cancer and may find applicability as a novel cancer biomarker.Prostate-specific antigen (PSA) 1 testing has revolutionized the management of patients with prostate cancer (1). The PSA gene (KLK3) is a member of the human tissue kallikrein gene family, which is also comprised of human glandular kallikrein 2 (KLK2) (2) and pancreatic/renal kallikrein (KLK1) (3) genes. More recently, new serine proteases with a high degree of homology to the kallikrein genes were cloned (4 -9). The successful diagnostic use of PSA in prostate cancer suggests that other related or unrelated molecules might be discovered and serve as diagnostic tests for breast, ovarian, and other cancers. In addition to PSA, human glandular kallikrein 2 (encoded by the KLK2 gene) may be useful as an adjuvant diagnostic marker for prostate cancer (10). Accumulating evidence indicates that some members of the kallikrein gene family are implicated in carcinogenesis. The normal epithelial cell-specific 1 gene (NES1) was found to be a tumor suppressor (11) that is down-regulated during breast cancer progression. The zyme/ protease M/neurosin gene is expressed in primary breast cancers but is down-regulated at metastatic sites (4).The large size of the kallikrein gene family in other species, such as rat and mouse, where kallikreins are encoded by 13-24 genes (12-13), and the recent identification of new kallikreinlike genes suggested that the human kallikrein gene family may be larger than previously thought. The rodent kallikrein genes are located in clusters on chromosome 7, and the region between two mouse kallikrein genes in a cluster can be as small as 3-7 kb (14).In our efforts to identify new kallikrein-like genes that might be useful as diagnostic and/or prognostic markers for cancer, we studied a genomic area of Ïł300 kb around chromosome 19q13.3-q13.4, where the known human kallikrein genes are localized. We were able to identify three new kallikrein-like genes; KLK-L1 (for kallikrein-like gene 1) (15) KLK-L2 (fo...